Phase I Study of ICP-332 in Healthy Subjects

Last updated: July 31, 2024
Sponsor: InnoCare Pharma Inc.
Overall Status: Active - Recruiting

Phase

1

Condition

Healthy Volunteers

Treatment

ICP-332 Placebo Tablets

ICP-332 Tablets

Clinical Study ID

NCT06530966
ICP-CL-00605
  • Ages 18-55
  • All Genders
  • Accepts Healthy Volunteers

Study Summary

A multiple ascending dose phase I study of ICP-332 in healthy subjects

Eligibility Criteria

Inclusion

Inclusion Criteria:

  1. Voluntarily sign the informed consent form

  2. Body mass index (BMI) of ≥ 18.5 kg/m2 and < 30 kg/m2

  3. Male or infertile female subjects who are between 18-55 years old (inclusive)

Exclusion

Exclusion Criteria:

  1. Significant current or past acute or chronic disease or condition.

  2. A history of tuberculosis or current active/latent infection.

  3. With a history of drug or food allergy, or allergy to any of the compositioncomponents of the study drug, or allergic disease.

  4. Subjects with clinically significant abnormalities in the screening examinations.

Study Design

Total Participants: 24
Treatment Group(s): 2
Primary Treatment: ICP-332 Placebo Tablets
Phase: 1
Study Start date:
July 23, 2024
Estimated Completion Date:
December 25, 2024

Connect with a study center

  • Pharmaron CPC Inc.

    Baltimore, Maryland 21201
    United States

    Active - Recruiting

  • Site Name

    Baltimore, Maryland 21201
    United States

    Active - Recruiting

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.